Navidea Biopharmaceuticals Chief Medical Officer Michael Rosol's 2022 pay slips 8% to $430K
Navidea Biopharmaceuticals reports 2022 executive compensation
By ExecPay News
Published: October 5, 2023
Navidea Biopharmaceuticals reported fiscal year 2022 executive compensation information on October 5, 2023.
In 2022, two executives at Navidea Biopharmaceuticals received on average a compensation package of $327K, a 31% decrease compared to previous year.
Average pay of disclosed executives at Navidea Biopharmaceuticals
Michael S. Rosol, Chief Medical Officer, received $430K in total, which decreased by 8% compared to 2021. 78% of Rosol's compensation, or $337K, was in salary. Rosol also received $81K in non-equity incentive plan, $3.6K in stock awards, as well as $8.2K in other compensation.
Erika L. Eves, Vice President, Finance & Administration, received a compensation package of $223K, which decreased by 6% compared to previous year. 81% of the compensation package, or $182K, was in salary.
Related executives
You may also like
Source: SEC filing on October 5, 2023.